Evidence map›Paper›PMID 30124034›Full record

ReviewSheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi2018

[Research advance of lateral flow assay labels].

Jing Jing, Zhizeng Wang

Abstract readEnglish AbstractReview
In one paragraph

Review in Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jing JingJoint National Laboratory for Antibody Drug Engineering, Key Lab of Cellular and Molecular Immunology, School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, P.R.China.
Zhizeng WangJoint National Laboratory for Antibody Drug Engineering, Key Lab of Cellular and Molecular Immunology, School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, P.R.China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lateral flow assay is widely used in the point-of-care testing on-site and in-home testing with the advantage of being simple, rapid, sensitive and cost-effective. Proper labels are the key factors in lateral flow assay. Traditional labels include colloidal gold, selenium nanoparticle, and carbon nanoparticle, among which the colloidal gold is most commonly used. Lateral flow assay has been improved as a result of the discovery of new labels, such as quantum dots and nanozyme recently. Meanwhile, transformation of qualitative detection to quantitative detection is gradually realized. This article aims at introducing the most often used and the latest lateral flow assay labels, providing a basis theoretical investigation on screening proper labels for lateral flow assay researchers.

Indexed as

colloidal goldlabelslateral flow assaynanozyme

Identifiers

PMID30124034
PMCPMC9935128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.